D. Raphael, G. Makuka, Abdu Hussein Mogella, Beatrice Kabuka, Rosemary T. Mushi, Collins Boamah
{"title":"LCZ-696(Sacubitril/缬沙坦)和sgl2抑制剂的使用:非洲农村心力衰竭伴射血分数降低(HFrEF)患者的真实世界经验案例系列","authors":"D. Raphael, G. Makuka, Abdu Hussein Mogella, Beatrice Kabuka, Rosemary T. Mushi, Collins Boamah","doi":"10.34257/gjmrfvol23is1pg1","DOIUrl":null,"url":null,"abstract":"Objective: To observe the outcomes of the use of both Angiotensin Receptor-Neprilysin inhibitor (ARNI) and sodium-glucose cotransport 2-inhibitor (SGLT2Ii) in terms of echocardiographic parameters, clinical symptoms, cardiovascular death, and Heart failure hospitalization in patient with heart failure reduced ejection fraction (HFrEF) in the hard-to-reach rural area of Africa.\nBackground: Angiotensin Receptor-Neprilysin inhibitor (ARNI) is preferred over angiotensin-converting enzymes inhibitor or an angiotensin II receptor blocker as foundation therapy for patients with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death, Heart failure hospitalization, and Heart failure symptoms. SGLT2 inhibitor (Dapagliflozin and Empagliflozin) is among the four foundation drugs in managing HFrEF.","PeriodicalId":93101,"journal":{"name":"Global journal of medical research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Theuse of LCZ-696(Sacubitril/Valsartan) and SGLT2inhibitors: A Real World Experience in a Rural African Patient with Heart Failure with Reduced Ejection Fraction (HFrEF). A Case Series\",\"authors\":\"D. Raphael, G. Makuka, Abdu Hussein Mogella, Beatrice Kabuka, Rosemary T. Mushi, Collins Boamah\",\"doi\":\"10.34257/gjmrfvol23is1pg1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To observe the outcomes of the use of both Angiotensin Receptor-Neprilysin inhibitor (ARNI) and sodium-glucose cotransport 2-inhibitor (SGLT2Ii) in terms of echocardiographic parameters, clinical symptoms, cardiovascular death, and Heart failure hospitalization in patient with heart failure reduced ejection fraction (HFrEF) in the hard-to-reach rural area of Africa.\\nBackground: Angiotensin Receptor-Neprilysin inhibitor (ARNI) is preferred over angiotensin-converting enzymes inhibitor or an angiotensin II receptor blocker as foundation therapy for patients with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death, Heart failure hospitalization, and Heart failure symptoms. SGLT2 inhibitor (Dapagliflozin and Empagliflozin) is among the four foundation drugs in managing HFrEF.\",\"PeriodicalId\":93101,\"journal\":{\"name\":\"Global journal of medical research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global journal of medical research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34257/gjmrfvol23is1pg1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global journal of medical research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34257/gjmrfvol23is1pg1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Theuse of LCZ-696(Sacubitril/Valsartan) and SGLT2inhibitors: A Real World Experience in a Rural African Patient with Heart Failure with Reduced Ejection Fraction (HFrEF). A Case Series
Objective: To observe the outcomes of the use of both Angiotensin Receptor-Neprilysin inhibitor (ARNI) and sodium-glucose cotransport 2-inhibitor (SGLT2Ii) in terms of echocardiographic parameters, clinical symptoms, cardiovascular death, and Heart failure hospitalization in patient with heart failure reduced ejection fraction (HFrEF) in the hard-to-reach rural area of Africa.
Background: Angiotensin Receptor-Neprilysin inhibitor (ARNI) is preferred over angiotensin-converting enzymes inhibitor or an angiotensin II receptor blocker as foundation therapy for patients with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death, Heart failure hospitalization, and Heart failure symptoms. SGLT2 inhibitor (Dapagliflozin and Empagliflozin) is among the four foundation drugs in managing HFrEF.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
